Business Context and Reporting Period
This Form 8-K was filed by Kiora Pharmaceuticals, Inc. (formerly EyeGate Pharmaceuticals, Inc.) on November 5, 2021, reporting events effective November 8, 2021. The filing documents a corporate rebranding initiative, including a legal name change, a change in ticker symbol, and a relocation of headquarters.
Financial Metrics
This filing is a current report regarding corporate governance and branding changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Corporate Name: Changed from EyeGate Pharmaceuticals, Inc. to Kiora Pharmaceuticals, Inc. via a merger with a wholly-owned subsidiary.
- Trading Symbol: Common stock will trade on the Nasdaq Capital Market under the new ticker symbol "KPRX" effective November 8, 2021.
- CUSIP Number: The CUSIP number for outstanding shares changed to 49721T101.
- Headquarters: Relocated to 1371 East 2100 South, Suite 200, Salt Lake City, Utah 84105.
- Bylaws: Amended and restated to reflect the name change.
Outlook and Management Commentary
Management announced a corporate rebranding initiative and the launch of a new website (www.kiorapharma.com) to serve as the central hub for investor relations information, including SEC filings and corporate governance documents. No specific financial guidance or risk factors related to operations were disclosed in this specific filing.
Key Facts for Investor Verification
- Verify the new ticker symbol "KPRX" on the Nasdaq Capital Market.
- Confirm the new CUSIP number 49721T101 for existing holdings.
- Note that existing stock certificates remain valid and do not require exchange.
- Update contact records to reflect the new Salt Lake City, Utah headquarters address.
- Access future press releases and filings via the new website, www.kiorapharma.com.